Complete response of metastatic BRAF V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report

被引：2

作者：

Lee, Sang Jae ^{[1
]}

Song, Si-Youn ^{[1
]}

Kim, Min Kyoung ^{[2
]}

Na, Hyung Gyun ^{[1
]}

Bae, Chang Hoon ^{[1
]}

Kim, Yong-Dae ^{[1
,3
]}

Choi, Yoon Seok ^{[1
]}

机构：

[1] Yeungnam Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, 170 Hyeonchung Ro, Daegu 42415, South Korea

[2] Yeungnam Univ, Coll Med, Dept Internal Med, Div Hematol Oncol, Daegu 42415, South Korea

[3] Yeungnam Univ, Reg Ctr Resp Dis, Med Ctr, Daegu 42415, South Korea

来源：

WORLD JOURNAL OF CLINICAL CASES | 2023年 / 11卷 / 27期

关键词：

Thyroid carcinoma; Anaplastic; BRAF; Dabrafenib; Trametinib; Chemotherapy; Adjuvant; Case report;

D O I：

10.12998/wjcc.v11.i27.6664

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND Anaplastic thyroid cancer (ATC) is a rare but aggressive type of thyroid carcinoma. BRAF V600E-mutation, which is found in 10%-50% of ATCs, is associated with poor prognosis. A recent clinical trial reported a substantial clinical benefit of concomitant treatment of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for treating BRAF V600E-mutant ATC. However, reports on patients with ATC treated with this regimen following surgery are lacking.CASE SUMMARYWe report the case of a 63-year-old female patient diagnosed with BRAF V600E-mutant ATC. Following three surgeries-total thyroidectomy, total laryngectomy, and neck dissection-she was diagnosed with lung metastasis during follow-up. The metastatic ATC was successfully treated with dabrafenib and trametinib. The patient achieved a complete response at the 32-mo follow-up.CONCLUSIONAdjuvant chemotherapy with dabrafenib plus trametinib is efficacious for treatment and prevention of recurrent ATC with BRAF mutation following surgery.

引用

页码：6664 / 6669

页数：6

共 9 条

[1] Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report [J].

Adachi, Yuta ;

Yanagimura, Naohiro ;

Suzuki, Chiaki ;

Ootani, Sakiko ;

Tanimoto, Azusa ;

Nishiyama, Akihiro ;

Yamashita, Kaname ;

Ohtsubo, Koushiro ;

Takeuchi, Shinji ;

Yano, Seiji .

BMC CANCER, 2020, 20 (01)

[2] Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature [J].

Arikan, Rukiye ;

Telli, Tugba Akin ;

Demircan, Nazim Can ;

Baoglu, Tugba ;

Ercelep, Ozlem ;

Atasoy, Beste Melek ;

ozguven, Salih ;

Dane, Faysal ;

Yumuk, Perran Fulden .

CURRENT PROBLEMS IN CANCER, 2021, 45 (02)

[3] 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force [J].

Bible, Keith C. ;

Kebebew, Electron ;

Brierley, James ;

Brito, Juan P. ;

Cabanillas, Maria E. ;

Clark, Thomas J., Jr. ;

Di Cristofano, Antonio ;

Foote, Robert ;

Giordano, Thomas ;

Kasperbauer, Jan ;

Newbold, Kate ;

Nikiforov, Yuri E. ;

Randolph, Gregory ;

Rosenthal, M. Sara ;

Sawka, Anna M. ;

Shah, Manisha ;

Shaha, Ashok ;

Smallridge, Robert ;

Wong-Clark, Carol K. .

THYROID, 2021, 31 (03) :337-386

[4] Novel treatments for anaplastic thyroid carcinoma [J].

Ferrari, Silvia Martina ;

Elia, Giusy ;

Ragusa, Francesca ;

Ruffilli, Ilaria ;

La Motta, Concettina ;

Paparo, Sabrina Rosaria ;

Patrizio, Armando ;

Vita, Roberto ;

Benvenga, Salvatore ;

Materazzi, Gabriele ;

Fallahi, Poupak ;

Antonelli, Alessandro .

GLAND SURGERY, 2020, 9 :S28-S42

[5] Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations [J].

Flaherty, Keith T. ;

Infante, Jeffery R. ;

Daud, Adil ;

Gonzalez, Rene ;

Kefford, Richard F. ;

Sosman, Jeffrey ;

Hamid, Omid ;

Schuchter, Lynn ;

Cebon, Jonathan ;

Ibrahim, Nageatte ;

Kudchadkar, Ragini ;

Burris, Howard A., III ;

Falchook, Gerald ;

Algazi, Alain ;

Lewis, Karl ;

Long, Georgina V. ;

Puzanov, Igor ;

Lebowitz, Peter ;

Singh, Ajay ;

Little, Shonda ;

Sun, Peng ;

Allred, Alicia ;

Ouellet, Daniele ;

Kim, Kevin B. ;

Patel, Kiran ;

Weber, Jeffrey .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (18) :1694-1703

[6] Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL) [J].

Gonzalez-Barrallo, Ines ;

Castellon Rubio, Victoria Eugenia ;

Medina, Javier ;

Espana, Sofia ;

Mujika, Karmele ;

Majem, Margarita ;

Aguado, Carlos ;

Cabrera Suarez, Miguel Angel ;

Palacio, Isabel ;

Osterloh, Lisa ;

Martinez-Fernandez, Alejandro ;

Garcia-Castano, Almudena .

MELANOMA RESEARCH, 2022, 32 (05) :343-352

[7] Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer- Real-World Outcomes From UK Centres [J].

Lorimer, C. ;

Cheng, L. ;

Chandler, R. ;

Garcez, K. ;

Gill, V. ;

Graham, K. ;

Grant, W. ;

Infirri, S. Sardo ;

Wadsley, J. ;

Wall, L. ;

Webber, N. ;

Wong, K. H. ;

Newbold, K. .

CLINICAL ONCOLOGY, 2023, 35 (01) :E60-E66

[8] Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study [J].

Subbiah, V ;

Kreitman, R. J. ;

Wainberg, Z. A. ;

Cho, J. Y. ;

Schellens, J. H. M. ;

Soria, J. C. ;

Wen, P. Y. ;

Zielinski, C. C. ;

Cabanillas, M. E. ;

Boran, A. ;

Ilankumaran, P. ;

Burgess, P. ;

Salas, T. Romero ;

Keam, B. .

ANNALS OF ONCOLOGY, 2022, 33 (04) :406-415

[9] Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer [J].

Subbiah, Vivek ;

Kreitman, Robert J. ;

Wainberg, Zev A. ;

Cho, Jae Yong ;

Schellens, Jan H. M. ;

Soria, Jean Charles ;

Wen, Patrick Y. ;

Zielinski, Christoph ;

Cabanillas, Maria E. ;

Urbanowitz, Gladys ;

Mookerjee, Bijoyesh ;

Wang, Dazhe ;

Rangwala, Fatima ;

Keam, Bhumsuk .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (01) :7-+

← 1 →